JJP Biologics to Present Nebaprubart LAD Data at Two European Conferences
JJP Biologics will showcase its anti-CD89 drug candidate at dermatology conferences in Germany and Austria this week.
Warsaw-based biotech JJP Biologics announced Monday that investigational data on nebaprubart, its first-in-class anti-CD89 antagonist antibody, will be presented at two major European scientific gatherings focused on autoimmune skin disorders.
The company's data on nebaprubart as a potential treatment for Linear IgA Dermatosis, a rare autoimmune blistering skin condition, will be delivered as an oral presentation at the IPPF Scientific Symposium on Pemphigus and Pemphigoid, held September 28-29 in Lübeck, Germany. A separate poster presentation is scheduled at the European Academy of Dermatology and Venereology Congress running September 30 through October 3 in Vienna, Austria.
Read more Law Firm Investigates MedImpact Data Breach Affecting SSNs, Health Data →
Nebaprubart is positioned by JJP Biologics as a precision antibody designed to block CD89, a receptor implicated in derailed immune pathways. The company describes itself as a clinical-stage, immune-focused biotech targeting autoimmune diseases and cancer. Linear IgA Dermatosis remains an area of significant unmet medical need with limited approved treatment options.
Presenting data at both an oral session and a poster format across two conferences in the same week signals the company's push to build scientific credibility for nebaprubart ahead of potential further clinical development. Appearances at IPPF and EADV, both regarded as key forums for dermatology and immunology researchers, could attract attention from potential partners or investors monitoring the rare skin disease space.
Continue reading at GlobeNewswire - Industry News on Financial Services.
